Liposomes as ‘smart’ pharmaceutical nanocarriers

Since the discovery of liposomes, these phospholipid ‘bubbles’ have received enormous attention to be recognized as ‘smart’ pharmaceutical nanocarriers. Recently, much effort has been directed to the development of so-called ‘smart’ stimuli-sensitive liposomes that will respond to certain internal or external stimuli, such as, pH, temperature, redox potential or magnetic field. These programmable delivery systems can also be made ‘multifunctional’ so as to expose certain functions in an orchestrated manner which can be readily modulated by the stimulus. In this article, the evolution of liposomes with emphasis on the recent advances in stimuli-sensitive liposomes has been reviewed.

[1]  T. Honda,et al.  Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice , 2008, Clinical Cancer Research.

[2]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[3]  Joachim Kohn,et al.  pH triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes. , 2006, Biomaterials.

[4]  M. Dewhirst,et al.  Hyperthermia mediated liposomal drug delivery , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[5]  L. Huang,et al.  pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. , 1986, Cancer research.

[6]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[7]  He Zhang,et al.  Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. , 2009, International journal of pharmaceutics.

[8]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[9]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[10]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[11]  Pallab Pradhan,et al.  Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Shono,et al.  Kinetic analysis of endocytosis and intracellular fate of liposomes in single macrophages. , 1995, Journal of biochemistry.

[13]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[14]  J. Zia,et al.  Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. , 2003, The Biochemical journal.

[15]  G. Hardee,et al.  Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. , 2003, Bioconjugate chemistry.

[16]  Raimon Sabaté,et al.  Preparation and characterization of extruded magnetoliposomes. , 2008, International journal of pharmaceutics.

[17]  S. Futaki,et al.  An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives , 2008, Analytical and bioanalytical chemistry.

[18]  F. Szoka,et al.  Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. , 2003, Biophysical journal.

[19]  In-Young Kim,et al.  Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes , 2008, Archives of pharmacal research.

[20]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[21]  D. Tzemach,et al.  Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. , 1999, Anti-cancer drugs.

[22]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[23]  J. Leroux,et al.  In vitro characterization of a novel polymeric-based pH-sensitive liposome system. , 2000, Biochimica et biophysica acta.

[24]  F. Khuri,et al.  A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.

[25]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[26]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  J. Schellens,et al.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.

[28]  D. Fischer,et al.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Vladimir P Torchilin,et al.  Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.

[30]  D. Thompson,et al.  Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[31]  S. Soenen,et al.  Surface functionalization of magnetoliposomes in view of improving iron oxide-based magnetic resonance imaging contrast agents: anchoring of gadolinium ions to a lipophilic chelate. , 2007, Analytical biochemistry.

[32]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[34]  K. Kono,et al.  Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[35]  R. Bankert,et al.  THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS , 2002, Journal of liposome research.

[36]  Bhawna Gupta,et al.  Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice , 2007, Cancer Immunology, Immunotherapy.

[37]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Qiang Zhang,et al.  Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. , 2005, Journal of pharmaceutical sciences.

[39]  H. Karanth,et al.  pH‐Sensitive liposomes‐principle and application in cancer therapy , 2007, The Journal of pharmacy and pharmacology.

[40]  V. Torchilin Liposomes as targetable drug carriers. , 1985, Critical reviews in therapeutic drug carrier systems.

[41]  P. Cullis,et al.  Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. , 1996, Biochemistry.

[42]  V. Cardoso,et al.  Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. , 2007, Life sciences.

[43]  J. Hughes,et al.  Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. , 1999, Bioconjugate chemistry.

[44]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[45]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[46]  Kyung-Dall Lee,et al.  Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. , 2005, Molecular pharmaceutics.

[47]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[48]  K. Fujimoto,et al.  A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating. , 2006, Colloids and surfaces. B, Biointerfaces.

[49]  J. Haveman,et al.  The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  A. Gabizon,et al.  Liposome circulation time and tumor targeting: implications for cancer chemotherapy , 1995 .

[51]  James B. Mitchell,et al.  Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. , 2002, Cancer research.

[52]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[53]  Olivier Meyer,et al.  Copolymers of N‐isopropylacrylamide can trigger pH sensitivity to stable liposomes , 1998, FEBS letters.

[54]  I. Ojima,et al.  Recent advances in tumor-targeting anticancer drug conjugates. , 2005, Bioorganic & medicinal chemistry.

[55]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Lafleur,et al.  On the characterization of pH-sensitive liposome/polymer complexes. , 2003, Biomacromolecules.

[57]  R. Scheule,et al.  Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. , 1997, Human gene therapy.

[58]  K. Kono,et al.  Temperature sensitization of liposomes using copolymers of N-isopropylacrylamide. , 1999, Bioconjugate chemistry.

[59]  P. Low,et al.  Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[60]  M. Zignani,et al.  Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.

[61]  I. Rubinstein,et al.  VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[62]  S. Yamada,et al.  Feasibility of magnetic liposomes as a targeting device for drugs. , 1986, Chemical & pharmaceutical bulletin.

[63]  Y. Oh,et al.  Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Vladimir P Torchilin,et al.  Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. , 2008, Biopolymers.

[65]  Vladimir P Torchilin,et al.  Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[67]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[68]  Samuel Zalipsky,et al.  Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol) , 1996, FEBS letters.

[69]  You Han Bae,et al.  Drug targeting and tumor heterogeneity. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[70]  I Horikoshi,et al.  Magnetic targeting of thermosensitive magnetoliposomes to mouse livers in an in situ on-line perfusion system. , 1995, Life sciences.

[71]  N. Phillips,et al.  Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.

[72]  V. Torchilin,et al.  Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. , 2007, Bioconjugate chemistry.

[73]  S. Simões,et al.  Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides , 1998, Gene Therapy.

[74]  W. Hennink,et al.  Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. , 2007, Bioconjugate chemistry.

[75]  Paras N Prasad,et al.  Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. , 2006, Molecular pharmaceutics.

[76]  Ingrid Hilger,et al.  Thermal Ablation of Tumors Using Magnetic Nanoparticles: An In Vivo Feasibility Study , 2002, Investigative radiology.

[77]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[78]  J. Legendre,et al.  Delivery of Plasmid DNA into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes , 1992, Pharmaceutical Research.

[79]  H. Arai,et al.  Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. , 1990, The Journal of biological chemistry.

[80]  A. Gabizon,et al.  Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. , 1991, Biochimica et biophysica acta.

[81]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[82]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[83]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[84]  J. Behr,et al.  Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody‐derivatized polyethylenimines (PEI) , 1999, The journal of gene medicine.

[85]  F. Chang,et al.  Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  Hui Zhao,et al.  RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer , 2009, Journal of drug targeting.

[87]  Yukikazu Natori,et al.  Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. , 2009, Molecular pharmaceutics.

[88]  Qiang Zhang,et al.  Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo , 2005, Pharmaceutical Research.

[89]  F. Szoka,et al.  Low‐pH‐sensitive poly(ethylene glycol) (PEG)‐stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery , 2005, The journal of gene medicine.

[90]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[91]  A. Hoffman,et al.  pH-sensitive polymers that enhance intracellular drug delivery in vivo. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[92]  E. K. Park,et al.  Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. , 2004, Biomaterials.

[93]  K. Kono,et al.  Targetability and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immunoliposomes to tumor cells. , 2002, International journal of pharmaceutics.

[94]  K. Kono,et al.  Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. , 1997, Biochimica et biophysica acta.

[95]  Wenjin Guo,et al.  Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[96]  K Mechtler,et al.  The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. , 1994, The Journal of biological chemistry.

[97]  M. Yatvin,et al.  pH-sensitive liposomes: possible clinical implications. , 1980, Science.

[98]  D. Scherman,et al.  Design, synthesis, and evaluation of gadolinium cationic lipids as tools for biodistribution studies of gene delivery complexes. , 2003, Bioconjugate chemistry.

[99]  B Poole,et al.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[100]  K. Maruyama,et al.  Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. , 1991, Chemical & pharmaceutical bulletin.

[101]  M. Basu,et al.  Macrophage specific drug delivery in experimental leishmaniasis. , 2004, Current molecular medicine.

[102]  T. Ishida,et al.  Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. , 2001, Biochimica et biophysica acta.

[103]  C. M. Gupta,et al.  Tuftsin-bearing liposomes in treatment of macrophage-based infections. , 2000, Advanced drug delivery reviews.

[104]  Y. Kawashima,et al.  Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[105]  T. Allen,et al.  Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.

[106]  I. Hafez,et al.  Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior. , 2000, Biochimica et biophysica acta.

[107]  Yu Zhou,et al.  Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. , 2007, Journal of molecular biology.

[108]  W. Hennink,et al.  A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.

[109]  M. Dewhirst,et al.  Drug targeting using thermally responsive polymers and local hyperthermia. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[110]  A. Gabizon Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[111]  T. Allen The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system , 1994 .

[112]  T. Suhara,et al.  Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. , 2004, International journal of pharmaceutics.

[113]  Yechezkel Barenholz,et al.  Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.

[114]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[115]  P. Couvreur,et al.  "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. , 2004, Advanced drug delivery reviews.

[116]  S. Simões,et al.  Sterically Stabilized pH-sensitive Liposomes , 1997, The Journal of Biological Chemistry.

[117]  K. Kono,et al.  Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. , 2008, Bioconjugate chemistry.

[118]  P. Low,et al.  Diplasmenylcholine−Folate Liposomes: An Efficient Vehicle for Intracellular Drug Delivery† , 1998 .

[119]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[120]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[121]  R. Herrmann,et al.  EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells , 2006, Journal of drug targeting.

[122]  A M Tsatsakis,et al.  Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. , 2001, Biomaterials.

[123]  V. Torchilin,et al.  "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.

[124]  K. Kairemo,et al.  Targeted liposomal drug delivery in cancer. , 2004, Current pharmaceutical design.

[125]  T. Allen,et al.  Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. , 2004, Pharmacological research.

[126]  Wenjin Guo,et al.  Characterization of a novel diolein-based LPDII vector for gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[127]  Halina D. Inerowicz,et al.  Acid-Triggered Release from Sterically Stabilized Fusogenic Liposomes via a Hydrolytic DePEGylation Strategy† , 2003 .

[128]  C. Ehrhardt,et al.  In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[129]  C. Shapiro,et al.  Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.

[130]  P. Low,et al.  Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. , 1999, Journal of pharmaceutical sciences.

[131]  H. Honda,et al.  4‐S‐Cysteaminylphenol‐loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma , 2007, Cancer science.

[132]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[133]  S. Otto,et al.  Reversible covalent chemistry in drug delivery. , 2005, Current drug discovery technologies.

[134]  I. Saiki,et al.  Microdialysis assessment of 5-fluorouracil release from thermosensitive magnetoliposomes induced by an electromagnetic field in tumor-bearing mice. , 1998, Journal of drug targeting.

[135]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[136]  H. Shmeeda,et al.  Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors , 2006, Molecular Cancer Therapeutics.

[137]  Ajay Kumar Gupta,et al.  Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. , 2007, Nanomedicine.

[138]  Sanjay K. Jain,et al.  Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells , 2007, Journal of drug targeting.

[139]  R K Jain,et al.  Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[140]  T. Allen,et al.  A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.

[141]  Samuel Zalipsky,et al.  In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  J. Kamps,et al.  Uptake of Long-Circulating Immunoliposomes, Directed Against Colon Adenocarcinoma Cells, by Liver Metastases of Colon Cancer , 2000, Journal of drug targeting.

[143]  Q. Ping,et al.  Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. , 2009, International journal of pharmaceutics.

[144]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[145]  V. Torchilin,et al.  Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. , 2009, Molecular pharmaceutics.

[146]  J. Zhang,et al.  Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[147]  L. J. Lee,et al.  Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. , 2009, Journal of nanoscience and nanotechnology.

[148]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[149]  P. Cullis,et al.  Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. , 1991, Biochimica et biophysica acta.

[150]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[151]  T. Yang,et al.  Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.

[152]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[153]  F. Szoka,et al.  Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.

[154]  Werner Tjarks,et al.  A novel pH-sensitive liposome formulation containing oleyl alcohol. , 2002, Biochimica et biophysica acta.

[155]  Sérgio Simões,et al.  On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.

[156]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[157]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[158]  Robert J. Lee,et al.  Targeted drug delivery via folate receptors , 2008, Expert opinion on drug delivery.

[159]  V. Torchilin,et al.  Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[160]  G. Gregoriadis,et al.  Is half‐life of circulating liposomes determined by changes in their permeability? , 1982, FEBS letters.

[161]  Jong-Mok Kim,et al.  Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. , 2009, Bioconjugate chemistry.

[162]  Vladimir Torchilin,et al.  Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[163]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[164]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[165]  G. Scherphof,et al.  Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. , 1981, Biochimica et biophysica acta.

[166]  M. Dewhirst,et al.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.

[167]  D. Papahadjopoulos,et al.  pH‐sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules , 1985, FEBS letters.

[168]  T. Ishida,et al.  Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. , 2006, International journal of pharmaceutics.

[169]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[170]  F. Szoka,et al.  Chemical approaches to triggerable lipid vesicles for drug and gene delivery. , 2003, Accounts of chemical research.

[171]  K. Kono,et al.  Thermosensitive polymer-modified liposomes. , 2001, Advanced drug delivery reviews.

[172]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[173]  P. Steerenberg,et al.  Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. , 1988, Biochimica et biophysica acta.

[174]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[175]  Vladimir P Torchilin,et al.  Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes , 2007, Journal of drug targeting.

[176]  M. Hashida,et al.  Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[177]  P. Rose,et al.  Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. , 2005, The oncologist.

[178]  Florence Gazeau,et al.  Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. , 2006, Radiology.

[179]  K. Ulbrich,et al.  POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE , 2001, Journal of liposome research.

[180]  R. Kontermann,et al.  Immunoliposomes for cancer therapy. , 2006, Current opinion in molecular therapeutics.

[181]  David H. Thompson,et al.  Cytosolic drug delivery using pH- and light-sensitive liposomes. , 1999, Advanced drug delivery reviews.

[182]  James B. Mitchell,et al.  In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. , 1998, Cancer research.

[183]  K. Kono,et al.  Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups. , 1994, Biochimica et biophysica acta.

[184]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[185]  Udo Greiser,et al.  Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.

[186]  R. Bellamkonda,et al.  Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. , 2009, Biomaterials.

[187]  W. Shen,et al.  Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. , 2003, Advanced drug delivery reviews.

[188]  K. Mann,et al.  Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors. , 2005, Medical hypotheses.

[189]  R. Vile,et al.  Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[190]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[191]  Lin Zhu,et al.  Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. , 2009, International journal of pharmaceutics.

[192]  H. Shmeeda,et al.  Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.

[193]  P. Stauffer,et al.  Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. , 1994, Cancer research.

[194]  R. Mahato Water insoluble and soluble lipids for gene delivery. , 2005, Advanced drug delivery reviews.

[195]  H. Shmeeda,et al.  Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[196]  E. A. Leite,et al.  Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. , 2009, Life sciences.

[197]  L. Huang,et al.  Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. , 1989, Biochemistry.

[198]  K. Funato,et al.  Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. , 1992, Biochimica et biophysica acta.

[199]  L. Huang,et al.  Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen. , 1992, Biochimica et biophysica acta.

[200]  M. Bally,et al.  Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. , 1994, Cancer research.

[201]  V. Torchilin,et al.  Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody , 2009, Clinical Cancer Research.

[202]  K. Kono,et al.  Thermosensitive polymer-modified liposomes that release contents around physiological temperature. , 1999, Biochimica et biophysica acta.

[203]  Francis C. Szoka,et al.  pH-Sensitive Liposomes , 1994 .

[204]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[205]  T. Allen,et al.  Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.

[206]  L. Pilarski,et al.  Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells , 1999 .

[207]  Hiroyuki Honda,et al.  Medical application of functionalized magnetic nanoparticles. , 2005, Journal of bioscience and bioengineering.

[208]  R. B. Campbell,et al.  The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. , 2007, Biomaterials.

[209]  R Blumenthal,et al.  Design of liposomes for enhanced local release of drugs by hyperthermia. , 1978, Science.

[210]  M. Woodle Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. , 1993, Chemistry and physics of lipids.

[211]  D. Thompson,et al.  Triggerable plasmalogen liposomes: improvement of system efficiency. , 1996, Biochimica et biophysica acta.

[212]  E. Moase,et al.  Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer , 2008, Journal of drug targeting.

[213]  Andrew D. Miller,et al.  Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. , 2008, Bioconjugate chemistry.

[214]  E. Choi,et al.  Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine. , 2009, International journal of pharmaceutics.

[215]  C. Alving,et al.  Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[216]  Ho-Suk Choi,et al.  Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): drug release behavior and stability in the presence of serum. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[217]  M. Yessine,et al.  Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. , 2004, Advanced drug delivery reviews.